The 52-week incidence rates for gastrointestinal AEs for albiglutide and placebo were : 31.3 and 29.8 % , respectively ( diarrhoea : 11.3 and 8.6 % ; nausea : 10.7 and 11.3 % ; vomiting : 4.0 and 4.0 % ) .